MGI Palonosetron Study Shows Superiority To GSK Zofran; User Fee In July
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A pivotal study comparing MGI Pharma’s 5-HT3 antagonist palonosetron to GlaxoSmithKline’s market leader Zofran shows superior efficacy for palonosetron in prevention of chemotherapy-induced nausea and vomiting.
You may also be interested in...
MGI Aloxi approval
MGI Pharma's Aloxi (palonosetron) clears FDA July 25 for prevention of "acute nausea and vomiting associated with initial and repeat courses of moderately to highly emetogenic chemotherapy" and "prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy," making it the first 5-HT3 antagonist approved for delayed chemotherapy-induced nausea and vomiting. Marketing efforts will focus on Aloxi's differentiated labeling, superior clinical results and potential pharmacoeconomic benefits. MGI has pointed to the agent's greater affinity for 5-HT3 receptors and longer half-life as key distinguishing factors from GSK's Zofran, Aventis' Anzemet and Roche's Kytril (1Pharmaceutical Approvals Monthly June 1, 2003, p. 7). MGI also notes the potential for use with Merck's substance P antagonist Emend (aprepitant). Aloxi will be priced above the other 5-HT3 agents...
FDA NME Tally: Spring Thaw Brings Three March Approvals
FDA closed the first quarter of 2003 with three new molecular entity approvals, all in March.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011